Metabolic effects of estradiol versus testosterone in complete androgen insensitivity syndrome.
Androgen receptor
CAIS
Estradiol
Metabolism
Testosterone
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
19
01
2022
accepted:
10
02
2022
pubmed:
9
3
2022
medline:
3
6
2022
entrez:
8
3
2022
Statut:
ppublish
Résumé
To study differences in metabolic outcomes between testosterone and estradiol replacement in probands with complete androgen insensitivity syndrome (CAIS). In this multicentre, double-blind, randomized crossover trial, 26 women with CAIS were included of whom 17 completed the study. After a two-months run in phase with estradiol, probands either received transdermal estradiol followed by crossover to transdermal testosterone or vice versa. After six months, differences in lipids, fasting glucose, insulin, hematocrit, liver parameters and blood pressure between the treatment phases were investigated. Linear mixed models adjusted for period and sequence did not reveal major group differences according to treatment for the investigated outcomes. In each treatment group, there were however significant uniform changes in BMI and cholesterol. BMI increased significantly, following six months of estradiol ( + 2.7%; p = 0.036) as well as testosterone treatment ( + 2.8%; p = 0.036). There was also a significant increase in total ( + 10.4%; p = 0.001) and LDL-cholesterol ( + 29.2%; p = 0.049) and a decrease in HDL-cholesterol (-15.8%; p < 0.001) following six months of estradiol as well as six months of testosterone treatment (total cholesterol: + 14.6%; p = 0.008; LDL-cholesterol: + 39.1%; p = 0.005, HDL-cholesterol: -15.8%; p = 0.004). Other parameters remained unchanged. Transdermal estradiol as well as testosterone treatment in women with CAIS results in worsening in lipid profiles. Given the relatively small sample size, subtle group differences in other metabolic parameters may have remained undetected.
Identifiants
pubmed: 35258786
doi: 10.1007/s12020-022-03017-8
pii: 10.1007/s12020-022-03017-8
pmc: PMC9156500
doi:
Substances chimiques
Cholesterol, HDL
0
Testosterone
3XMK78S47O
Estradiol
4TI98Z838E
Cholesterol
97C5T2UQ7J
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
722-732Informations de copyright
© 2022. The Author(s).
Références
A. Berglund, T.H. Johannsen, K. Stochholm, M.H. Viuff, J. Fedder, K.M. Main et al. Incidence, prevalence, diagnostic delay, and clinical presentation of female 46, XY disorders of sex development. J. Clin. Endocrinol. Metab. 101(12), 4532–4540 (2016)
doi: 10.1210/jc.2016-2248
O. Hiort, W. Birnbaum, L. Marshall, L. Wünsch, R. Werner, T. Schröder et al. Management of disorders of sex development. Nat. Rev. Endocrinol. 10(9), 520–529 (2014)
doi: 10.1038/nrendo.2014.108
P.C. McDonald, J.D. Madden, P.F. Brenner, J.D. Wilson, P.K. Siiteri, Origin of estrogen in normal men and in women with testicular feminization. J. Clin. Endocrinol. Metab. 49(6), 905–916 (1979)
doi: 10.1210/jcem-49-6-905
U. Doehnert, S. Bertelloni, R. Werner, E. Dati, O. Hiort., Characteristic features of reproductive hormone profiles in late adolescent and adult females with complete androgen insensitivity syndrome. Sex Dev. 9(2), 69–74 (2015)
doi: 10.1159/000371464
W. Birnbaum, L. Marshall, R. Werner, A. Kulle, P.M. Holterhus, K. Rall, B. Köhler et al. Oestrogen versus androgen in hormone-replacement therapy for complete androgen insensitivity syndrome: a multicentre, randomised, double-dummy, double-blind crossover trial. Lancet. Diabetes Endocrinol. 6(10), 771–780 (2018)
doi: 10.1016/S2213-8587(18)30197-9
J.K. Ko, T.F. King, L. Williams, S.M. Creighton, G.S. Conway, Hormone replacement treatment choices in complete androgen insensitivity syndrome: an audit of an adult clinic. Endocr. Connect 6(6), 375–379 (2017)
doi: 10.1530/EC-17-0083
D. Reddy, Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3α-androstanediol and 17β-estradiol. Neuroscience. 129(1), 195–207 (2004)
doi: 10.1016/j.neuroscience.2004.08.002
E.R. Simpson, S.R. Davis., Minireview: Aromatase and the regulation of estrogen biosynthesis—some new perspectives. Endocrinology 142(11), 4589–4594 (2001)
doi: 10.1210/endo.142.11.8547
M.K. Auer, T. Ebert, M. Pietzner, J. Defreyne, J. Fuss, G.K. Stalla et al. Effects of sex hormone treatment on the metabolic syndrome in transgender individuals: focus on metabolic cytokines. J. Clin. Endocrinol. Metab. 103(2), 790–802 (2018)
doi: 10.1210/jc.2017-01559
S.C. Manolagas, C.A. O’brien, M. Almeida., The role of estrogen and androgen receptors in bone health and disease. Nat. Rev. Endocrinol. 9(12), 699 (2013)
doi: 10.1038/nrendo.2013.179
E.P. Smith, B. Specker, B.E. Bachrach, K. Kimbro, X. Li, M.F. Young et al. Impact on bone of an estrogen receptor-α gene loss of function mutation. J. Clin. Endocrinol. Metab. 93(8), 3088–3096 (2008)
doi: 10.1210/jc.2007-2397
E. Dati, G. Baroncelli, S. Mora, G. Russo, F. Baldinotti, D. Parrini et al. Body composition and metabolic profile in women with complete androgen insensitivity syndrome. Sex Dev. 3(4), 188–193 (2009)
doi: 10.1159/000228719
R.S. Swerdloff, C. Wang, G. Cunningham, A. Dobs, A. Iranmanesh, A.M. Matsumoto et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J. Clin. Endocrinol. Metab. 85(12), 4500–4510 (2000)
pubmed: 11134099
https://www.pmda.go.jp/drugs/2006/P200600048/340052000_21800AMY10135_B104_2.pdf
A. Kulle, F.G. Riepe, D. Melchior, O. Hiort, P. Holterhus, A novel ultrapressure liquid chromatography tandem mass spectrometry method for the simultaneous determination of androstenedione, testosterone, and dihydrotestosterone in pediatric blood samples: Age-and sex-specific reference data. J. Clin. Endocrinol. Metab. 95(5), 2399–2409 (2010)
doi: 10.1210/jc.2009-1670
A. Kulle, M. Welzel, P.M. Holterhus, F. Riepe, Principles and clinical applications of liquid chromatography—tandem mass spectrometry for the determination of adrenal and gonadal steroid hormones. J. Endocrinol. Invest. 34(9), 702–708 (2011)
pubmed: 21738000
T. Reinehr, A. Kulle, A. Barth, J. Ackermann, N. Lass, P.M. Holterhus, Sex hormone profile in pubertal boys with gynecomastia and pseudogynecomastia. J. Clin. Endocrinol. Metab. 105(4), e1025–e1032 (2020)
doi: 10.1210/clinem/dgaa044
P. Björntorp, The regulation of adipose tissue distribution in humans. Int. J. Obes. (Lond) 20(4), 291–302 (1996)
F. Mauvais-Jarvis, Estrogen and androgen receptors: Regulators of fuel homeostasis and emerging targets for diabetes and obesity. Trends Endocrinol. Metab. 22(1), 24–33 (2011)
doi: 10.1016/j.tem.2010.10.002
G. Wade, J. Gray, T. Bartness, Gonadal influences on adiposity. Int. J. Obes. (Lond) 9(Suppl 1), 83–92 (1985)
M. Mohamed, A. Abdel-Rahman, Effect of long-term ovariectomy and estrogen replacement on the expression of estrogen receptor gene in female rats. Eur. J. Endocrinol. 142(3), 307–314 (2000)
doi: 10.1530/eje.0.1420307
J. Haarbo, U. Marslew, A. Gotfredsen, C. Christiansen, Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism 40(12), 1323–1326 (1991)
doi: 10.1016/0026-0495(91)90037-W
J.S. Finkelstein, H. Lee, S.A.M. Burnett-Bowie, J.C. Pallais, E.W. Yu, L.F. Borges et al. Gonadal steroids and body composition, strength, and sexual function in men. NEJM. 369(11), 1011–1022 (2013)
doi: 10.1056/NEJMoa1206168
C. Carani, K. Qin, M. Simoni, M. Faustini-Fustini, S. Serpente, J. Boyd, K.S. Korach et al. Effect of testosterone and estradiol in a man with aromatase deficiency. NEJM. 337(2), 91–95 (1997)
doi: 10.1056/NEJM199707103370204
E.P. Smith, J. Boyd, G.R. Frank, H. Takahashi, R.M. Cohen, B. Specker et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. NEJM. 331(16), 1056–1061 (1994)
doi: 10.1056/NEJM199410203311604
L. Ibáñez, N. Potau, M.V. Marcos, F. de Zegher, Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. J. Clin. Endocrinol. Metab. 85(9), 3251–3255 (2000)
pubmed: 10999817
G.A. Laughlin, V. Goodell, E. Barrett-Connor, Extremes of endogenous testosterone are associated with increased risk of incident coronary events in older women. J. Clin. Endocrinol. Metab. 95(2), 740–747 (2010)
doi: 10.1210/jc.2009-1693
C. Sievers, J. Klotsche, L. Pieper, H.J. Schneider, W. März, H.U. Wittchen et al. Low testosterone levels predict all-cause mortality and cardiovascular events in women: a prospective cohort study in German primary care probands. Eur. J. Endocrinol. 163(4), 699–708 (2010)
doi: 10.1530/EJE-10-0307
M. Klaver, C. De Blok, C. Wiepjes, N.M. Nota, M.J. Dekker, R. de Mutsert et al. Changes in regional body fat, lean body mass and body shape in trans persons using cross-sex hormonal therapy: results from a multicenter prospective study. Eur. J. Endocrinol. 178(2), 163–171 (2018)
doi: 10.1530/EJE-17-0496
P. Tsimaris, E. Deligeoroglou, N. Athanasopoulos, E. Economou, K. Stamatelopoulos, D. Rizos et al. The effect of hormone therapy on biochemical and ultrasound parameters associated with atherosclerosis in 46, XY DSD individuals with female phenotype. Gynecol. Endocrinol. 30(10), 721–725 (2014)
doi: 10.3109/09513590.2014.925868
P. Wahl, C. Walden, R. Knopp, J. Hoover, R. Wallace, G. Heiss et al. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. NEJM. 308(15), 862–867 (1983)
doi: 10.1056/NEJM198304143081502
D.D. Bradley, J. Wingerd, D.B. Petitti, R.M. Krauss, S. Ramcharan., Serum high-density-lipoprotein cholesterol in women using oral contraceptives, estrogens and progestins. NEJM. 299(1), 17–20 (1978)
doi: 10.1056/NEJM197807062990104
S. Bertelloni, E. Dati, G.I. Baroncelli, Disorders of sex development: hormonal management in adolescence. Gynecol. Endocrinol. 24(6), 339–346 (2008)
doi: 10.1080/09513590802055708
M. Vrablik, T. Fait, J. Kovar, R. Poledne, R. Ceska., Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins. Metabolism 57(8), 1088–1092 (2008)
doi: 10.1016/j.metabol.2008.03.012
M.P. Goodman, Are all estrogens created equal? A review of oral vs. transdermal therapy. J. Women Health 21(2), 161–169 (2012)
doi: 10.1089/jwh.2011.2839
E. Bachman, T.G. Travison, S. Basaria, M.N. Davda, W. Guo, M. Li et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. J. Gerontol. A. Biol. Sci. Med. Sci. 69(6), 725–735 (2014)
doi: 10.1093/gerona/glt154
M.K. Auer, A. Cecil, Y. Roepke, C. Bultynck, C. Pas, J. Fuss et al. 12-months metabolic changes among gender dysphoric individuals under cross-sex hormone treatment: a targeted metabolomics study. Sci. Rep. 6(1), 1–10 (2016)
doi: 10.1038/srep37005
V. Rochira, L. Zirilli, B. Madeo, L. Maffei, C. Carani, Testosterone action on erythropoiesis does not require its aromatization to estrogen: insights from the testosterone and estrogen treatment of two aromatase-deficient men. J. Steroid Biochem. Mol. Biol. 113(3–5), 189–194 (2009)
doi: 10.1016/j.jsbmb.2008.12.007
M.W. Greenwald, O.S. Gluck, E. Lang, V. Rakov. Oral hormone therapy with 17β-estradiol and 17β-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: Dose-dependent effects, Menopause. 12(6), 741–748
G. Gava, I. Mancini, I. Orsili, S. Bertelloni, S. Alvisi, R. Seracchioli, M.C. Meriggiola, Bone mineral density, body composition and metabolic profiles in adult women with complete androgen insensitivity syndrome and removed gonads using oral or transdermal estrogens. Eur. J. Endocrinol. 181(6), 711–718 (2019)
doi: 10.1530/EJE-19-0383
J.E. Ostberg, C. Storry, A.E. Donald, M.J. Attar, J.P. Halcox, G.S. Conway., A dose-response study of hormone replacement in young hypogonadal women: Effects on intima media thickness and metabolism. Clin. Endocrinol. (Oxf) 66(4), 557–564 (2007)
M.K. Auer, L. Paizoni, L.C. Hofbauer, M. Rauner, Y. Chen, H. Schmidt, A. Huebner, M. Bidlingmaier, N. Reisch, Effects of androgen excess and glucocorticoid exposure on bone health in adult patients with 21-hydroxylase deficiency. J. Steroid Biochem. Mol. Biol. 204, 105734 (2020)
N. Singh-Ospina, S. Maraka, R. Rodriguez-Gutierrez, C. Davidge-Pitts, T.B. Nippoldt, L.J. Prokop et al. Effect of Sex Steroids on the Bone Health of Transgender Individuals: A Systematic Review and Meta-Analysis. J. Clin. Endocrinol. Metab. 102(11), 3904–3913 (2017)
doi: 10.1210/jc.2017-01642